Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch